Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

समान संसाधन

• Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
  द्वारा: Gengwei Huo, और अन्य
  प्रकाशित: (2023-02-01)
• First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
  द्वारा: Wenjie Liu, और अन्य
  प्रकाशित: (2023-07-01)
• Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
  द्वारा: Wenjie Liu, और अन्य
  प्रकाशित: (2024-02-01)
• Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
  द्वारा: Maojin You, और अन्य
  प्रकाशित: (2023-09-01)
• An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
  द्वारा: Michele Bartoletti, और अन्य
  प्रकाशित: (2022-07-01)